Predict your next investment

Venture Capital
sofinnova.fr

See what CB Insights has to offer

Investments

358

Portfolio Exits

76

Funds

17

Partners & Customers

1

About Sofinnova Partners

Sofinnova Partners is a European venture capital firm specializing in Life Sciences. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a founding and lead investor in start-ups and corporate spin-offs.

Sofinnova Partners Headquarter Location

17, rue de Surène

Paris, 75008,

France

+33 (0)1 5305-4100

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Sofinnova Partners

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Sofinnova Partners in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Latest Sofinnova Partners News

Sofinnova Partners Raises €150M for Sofinnova Industrial Biotech II

Jan 3, 2022

Sofinnova Partners Raises €150M for Sofinnova Industrial Biotech II January 3, 2022 By Lynda Kiernan-Stone, Global AgInvesting Media Leading European life sciences venture capital firm Sofinnova Partners announced it has raised €150 million (US$169.4 million) for its Sofinnova Industrial Biotech II Fund. Joško Bobanović, partner at Sofinnova Industrial Biotech Fund, commented, “We are grateful for the confidence demonstrated by our investors, a large majority of whom are returning and a significant number of new investors joining from across the globe, reflecting the growing importance and prioritization of this sector.” With offices in Paris, London, and Milan, Sofinnova was a sustainability pioneer, launching its Sofinnova Green Seed Fund more than a decade ago. As part of this strategy, and as an early-stage environmental impact fund, the Sofinnova Industrial Biotech II Fund will continue to finance early-stage companies harnessing biotechnology to create sustainable solutions in the food, agriculture, chemical, and materials sectors. “The fundraise attests to the success of our strategy over the past decade and the growing understanding of how biotech can help to address global environmental challenges such as climate change, biodiversity, pollution, and food waste,” said Bobanović. Founded in 1972, Sofinnova Partners has more than 50 years of experience backing over 500 companies toward its mission of creating global market leaders. Today, Sofinnova has more than €2.5 billion (US$2.6 billion) in capital under management. And under this umbrella, found in the portfolio of the Sofinnova Industrial Biotech II Fund, are a range of companies including: Biotalys and Micropep Technologies: Two companies developing bio-based crop protection solutions;   Afyren and Comet Bio: Two companies upcycling agricultural waste into chemicals, food, or feed ingredients; DMC Biotechnologies, Protera, Biosyntia, and Microphyt: Companies using fermentation to create food ingredients; and  DNA Script and EnginZyme: Two companies that are biologically producing new chemicals and materials. Only weeks ago, in mid-December 2021, Sofinnova also led a $13 million Series A for Meiogenix , a Paris-based agricultural biotech company using gene and chromosome editing to create greater genetic diversity in our food and agricultural systems. Through its platform, Meiogenix has developed a novel approach to common challenges in agriculture, and key issues being faced by our global food systems and industries. By applying gene and chromosome editing technologies, Meiogenix is able to accelerate the natural generation of biodiversity through the mixing of parental genomes during plant reproduction. With collaborations already in place with Cornell and Bayer, the Meiogenix platform is addressing the $50 billion commercial seed market and breeding capabilities of the world’s largest crops such as corn, wheat, rice, soybeans, and tomatoes. At the time, Michael Krel, partner at Sofinnova Partners, and a key member of the Sofinnova Industrial Biotech Funds, said , “This investment reflects our expanding interest in the application of biotech in agriculture.” Bobanović noted that a large majority of the investors engaged in backing the Industrial Biotech II Fund are returning investors, while a significant portion are new investors joining from around the world, reflecting the mounting importance and prioritization of this investment class. Antoine Papiernik, chairman and managing partner at Sofinnova Partners, added, “Sofinnova is a leader across the life sciences value chain and we were one of the first to see early on the power of biotechnology to create sustainable solutions. We have one of the most accomplished VC teams in industrial biotech and are now more empowered to continue doing what we have been doing for 50 years: Partnering with exceptional entrepreneurs to transform groundbreaking science into the businesses of the future.”   – Lynda Kiernan-Stone is editor with GAI Media, and is managing editor and daily contributor for Global AgInvesting’s  AgInvesting Weekly News  and   Agtech Intel News , as well as HighQuest Group’s  Oilseed & Grain News . She can be reached at  lkiernan-stone@

Sofinnova Partners Investments

358 Investments

Sofinnova Partners has made 358 investments. Their latest investment was in NorthSea Therapeutics as part of their Series C on December 12, 2021.

CBI Logo

Sofinnova Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/17/2021

Series C

NorthSea Therapeutics

$80M

Yes

5

12/14/2021

Seed VC

Endoron Medical

$5M

Yes

3

12/14/2021

Series A

Meiogenix

$13M

Yes

1

12/2/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

11/29/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/17/2021

12/14/2021

12/14/2021

12/2/2021

11/29/2021

Round

Series C

Seed VC

Series A

Series B

Series C

Company

NorthSea Therapeutics

Endoron Medical

Meiogenix

Subscribe to see more

Subscribe to see more

Amount

$80M

$5M

$13M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

5

3

1

10

10

Sofinnova Partners Portfolio Exits

76 Portfolio Exits

Sofinnova Partners has 76 portfolio exits. Their latest portfolio exit was CinCor Pharma on January 07, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/7/2022

IPO

2

11/17/2021

Acquired

2

9/29/2021

IPO

2

8/31/2021

Acquired

Subscribe to see more

Subscribe to see more

10

7/1/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/7/2022

11/17/2021

9/29/2021

8/31/2021

7/1/2021

Exit

IPO

Acquired

IPO

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

2

2

10

10

Sofinnova Partners Acquisitions

1 Acquisition

Sofinnova Partners acquired 1 company. Their latest acquisition was NovusPharma on September 20, 1999.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/20/1999

Convertible Note

$99M

Management Buyout

1

Date

9/20/1999

Investment Stage

Convertible Note

Companies

Valuation

$99M

Total Funding

Note

Management Buyout

Sources

1

Sofinnova Partners Fund History

17 Fund Histories

Sofinnova Partners has 17 funds, including Sofinnova Industrial Biotech II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

11/17/2021

Sofinnova Industrial Biotech II

$169.61M

1

10/19/2021

Sofinnova Capital X

$549.69M

1

7/13/2021

MD Start III

$75M

2

3/3/2021

Sofinnova Crossover Fund

$99M

10

10/17/2019

Sofinnova Capital IX

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

11/17/2021

10/19/2021

7/13/2021

3/3/2021

10/17/2019

Fund

Sofinnova Industrial Biotech II

Sofinnova Capital X

MD Start III

Sofinnova Crossover Fund

Sofinnova Capital IX

Fund Type

Subscribe to see more

Status

Subscribe to see more

Amount

$169.61M

$549.69M

$75M

$99M

$99M

Sources

1

1

2

10

10

Sofinnova Partners Partners & Customers

1 Partners and customers

Sofinnova Partners has 1 strategic partners and customers. Sofinnova Partners recently partnered with Fondazione Telethon on February 2, 2018.

Date

Type

Business Partner

Country

News Snippet

Sources

2/28/2018

Partner

Fondazione Telethon

Italy

CP-DL Capolino-Perlingieri & Leone advise on Sofinnova Partners and Fondazione Telethon joint venture

CP-DL Capolino-Perlingieri & Leone has advised Fondazione Telethon on the structuring of a joint venture with Sofinnova Partners , a leading European life-sciences venture capital fund , in relation to the formation of the Sofinnova-Telethon Fund , the first Italian fund on technology transfer entirely dedicated to the establishment of new Italian start-up companies in the biotech industry , focusing on genetic/rare diseases .

1

Date

2/28/2018

Type

Partner

Business Partner

Fondazione Telethon

Country

Italy

News Snippet

CP-DL Capolino-Perlingieri & Leone advise on Sofinnova Partners and Fondazione Telethon joint venture

CP-DL Capolino-Perlingieri & Leone has advised Fondazione Telethon on the structuring of a joint venture with Sofinnova Partners , a leading European life-sciences venture capital fund , in relation to the formation of the Sofinnova-Telethon Fund , the first Italian fund on technology transfer entirely dedicated to the establishment of new Italian start-up companies in the biotech industry , focusing on genetic/rare diseases .

Sources

1

Sofinnova Partners Team

11 Team Members

Sofinnova Partners has 11 team members, including current Managing Partner, Denis J. Lucquin.

Name

Work History

Title

Status

Denis J. Lucquin

Managing Partner

Current

Antoine Papiernik

Unilever

Managing Partner

Current

Henrijette Richter

Novo Holdings, Vækstfonden, and Novo Nordisk

Managing Partner

Current

Monique Saulnier

Managing Partner

Current

Graziano Seghezzi

Managing Partner

Current

Name

Denis J. Lucquin

Antoine Papiernik

Henrijette Richter

Monique Saulnier

Graziano Seghezzi

Work History

Unilever

Novo Holdings, Vækstfonden, and Novo Nordisk

Title

Managing Partner

Managing Partner

Managing Partner

Managing Partner

Managing Partner

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.